Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PrEP

- PMLiVE

NHS England launches hepatitis C screening scheme to reach 2030 elimination goal

The new scheme could help diagnose up to 80,000 people who do not know they have hepatitis C

- PMLiVE

Gilead announces positive Biktarvy data for HIV and hepatitis B

The results were presented at the 24th International AIDS Conference

- PMLiVE

GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention

The agreement aims to expand access to HIV prevention in the developing world

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on Lymphoma

Spotlight on LymphomaAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Dr Loretta Nastoupil, US, on the most important abstracts to look out for in...

Medscape Education Global

- PMLiVE

MEDSCAPE EDUCATION: The Human Story in Virtual Patient Simulation

WHAT'S THE STORYStories are shared experiences, where meaning-centered approaches and coping strategies ascribe cultural meaningto events and emotions; a way to merge the individual and the collective experience into the...

Medscape Education Global

- PMLiVE

It’s a Medscape wrap for EHA2022

EHA2022 Hybrid Congress has now come to a close with the Thematic Days finishing last week. The Medscape team were delighted to connect with so many physicians, colleagues and supporters...

Medscape Education Global

- PMLiVE

A Medscape Oncology exclusive preview

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. We are the largest medical education provider, delivering precision education for actionable outcomes across 30+ specialties in...

Medscape Education Global

Roche Basel Switzerland

Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure

The partnership is focused on helping patients with HIV and TB in low- and middle-income countries

- PMLiVE

Gilead shares results from HIV trial for lenacapavir

The results were presented at the 29th Conference on Retroviruses and Opportunistic Infections – virtual CROI 2022

- PMLiVE

FDA issues approval for Janssen’s HIV drug Cabenuva

The injectable treatment for adults with HIV can be administered every two months

- PMLiVE

Vir Biotech launches new research programme for HIV and malaria prevention

Using antibody research, Vir will combine its existing immunology and virology expertise with the Gates Foundation

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links